Treating rosacea with botulism toxin : Protocol for a systematic review and meta-analysis
© 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC..
BACKGROUND: Rosacea is a chronic inflammatory disease usually associated with persistent erythema and periodic flushing. This disease is difficult to treat, and the outcomes are often unsatisfactory and prone to recurrence. In recent years, botulinum toxin has been used as a new treatment for rosacea; however, its efficacy and safety remain under discussion. Although a systematic review of the effectiveness and safety of botulinum toxin has been previously conducted by other researchers, our systematic review and meta-analysis evaluate the efficacy of botulinum toxin from a more comprehensive and detailed perspective to provide evidence for clinicians.
METHODS: Any study using botulinum toxin for the treatment of rosacea was considered for the analysis.
RESULTS: A total of 22 studies were included, 9 of which were randomized controlled trials involving 720 subjects. After treatment, all studies showed varying degrees of improvement in patient signs and symptoms along with reduced Clinician's Erythema Assessment (CEA) scores. The improvement was maintained for several months, and the adverse effects were mild and self-limiting.
CONCLUSION: Botulinum toxin may be an effective treatment for patients with rosacea; however, further clinical evidence is needed to confirm its long-term efficacy and side effects. The study was preregistered with Prospero (CRD42022358911).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of cosmetic dermatology - 23(2024), 1 vom: 29. Jan., Seite 44-61 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Guanjin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Botulinum Toxins, Type A |
|---|
| Anmerkungen: |
Date Completed 02.01.2024 Date Revised 02.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jocd.15962 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361040466 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361040466 | ||
| 003 | DE-627 | ||
| 005 | 20240108140732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jocd.15962 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM361040466 | ||
| 035 | |a (NLM)37605478 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Guanjin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treating rosacea with botulism toxin |b Protocol for a systematic review and meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.01.2024 | ||
| 500 | |a Date Revised 02.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Rosacea is a chronic inflammatory disease usually associated with persistent erythema and periodic flushing. This disease is difficult to treat, and the outcomes are often unsatisfactory and prone to recurrence. In recent years, botulinum toxin has been used as a new treatment for rosacea; however, its efficacy and safety remain under discussion. Although a systematic review of the effectiveness and safety of botulinum toxin has been previously conducted by other researchers, our systematic review and meta-analysis evaluate the efficacy of botulinum toxin from a more comprehensive and detailed perspective to provide evidence for clinicians | ||
| 520 | |a METHODS: Any study using botulinum toxin for the treatment of rosacea was considered for the analysis | ||
| 520 | |a RESULTS: A total of 22 studies were included, 9 of which were randomized controlled trials involving 720 subjects. After treatment, all studies showed varying degrees of improvement in patient signs and symptoms along with reduced Clinician's Erythema Assessment (CEA) scores. The improvement was maintained for several months, and the adverse effects were mild and self-limiting | ||
| 520 | |a CONCLUSION: Botulinum toxin may be an effective treatment for patients with rosacea; however, further clinical evidence is needed to confirm its long-term efficacy and side effects. The study was preregistered with Prospero (CRD42022358911) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a botulinum toxin type A | |
| 650 | 4 | |a external application | |
| 650 | 4 | |a intradermal injection | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a rosacea | |
| 650 | 7 | |a Botulinum Toxins, Type A |2 NLM | |
| 650 | 7 | |a EC 3.4.24.69 |2 NLM | |
| 700 | 1 | |a Yang, Qifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yuanen |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Huilan |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Hongbin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cosmetic dermatology |d 2002 |g 23(2024), 1 vom: 29. Jan., Seite 44-61 |w (DE-627)NLM166816639 |x 1473-2165 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:44-61 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jocd.15962 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 29 |c 01 |h 44-61 | ||